37

CLAIMS

1. A compound according to Formula I, wherein

Formula I

5

X is O, NOH, NO(1-4C)alkyl, NO(1-4C)acyl;

A1-A5 are C, substituted with R1, or N, provided that at least one and not more than three of A1-A5 are N; or

one or two of A1, A2 and A5 are N, and the others are C, substituted with R1, and A3 and A4 together represent a fused benzo ring or a fused five- or six-membered nitrogen-containing aromatic ring, both optionally substituted with one or more halogen and/or (1-4C)alkyl;

each R1 is independently selected from H, halogen, (1-4C)alkyl and (1-4C)alkoxy;

R2 is H, (1-4C)alkyl, or (1-6C) alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and

R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl; or

R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl); or

R2 is H or (1-4C)alkyl; and

10

15

20

38

5

10

15

(·

20

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring;

R5 is H or (1-4C)alkyl;

or a pharmaceutically acceptable salt and/or hydrate form and/or prodrug thereof.

- A compound according to claim 1 characterised in that A1-A5 are C, substituted with R1, or N, provided that at least one and not more than three of A1-A5 are N.
- 3. A compound according to claim 1 characterised in that one or two of A1, A2 and A5 are N, and the others are C, substituted with R1, and A3 and A4 together represent a fused benzo ring or a fused five- or six-membered nitrogen-containing aromatic ring, both optionally substituted with halogen and/or (1-4C)alkyl.
- 4. A compound according to claim 1 characterised in that R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or
- 5. A compound according to claim 1, characterised in that R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.
- 6. A compound according to claim 1, characterised in that R2 is H or (1-4C)alkyl; and

more halogen and/or (1-4C)alkyl.

WO 2005/092912

39

5

10

15

20

25

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.

- A compound according to claim 2, characterised in that
 R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an
 - (6-10C)aryl group, which is optionally substituted with one or more halogen

and/or (1-4C)alkyl; and

R3 is H or (1-4C)alkyl optionally substituted with one or more halogen; and R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl.

- 8. A compound according to claim 2, characterised in that R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.
- A compound according to claim 2, characterised in that
 R2 is H or (1-4C)alkyl; and
 R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated
 carbocyclic ring.
- 10. A compound according to claim 3, characterised in that
 R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an
 (6-10C)aryl group which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and
 R3 is H or (1-4C)alkyl optionally substituted with one or more halogen; and
 R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or
- 30 11. A compound according to claim 3, characterised in that

 R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and

more halogen and/or (1-4C)alkyl.

	\sim
71	11

10

20

R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.

- 12. A compound according to claim 3, characterised in that

 R2 is H or (1-4C)alkyl; and

 R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.
 - 13. A compound according to claim 1, characterised in that X is O.
 - 14. A compound according to claim 4, characterised in that R4 is cyclopropyl.
 - 15. A compound according to claim 5, characterised in that R4 is cyclopropyl.
- 16. A compound according to claim 2, characterised in that A1, A3, A4 and A5 are C, substituted with R1, and A2 is N.
 - 17. A compound according to claim 4, characterised in that
- 18. A compound according to claim 13, characterised in that
 A1, A3, A4 and A5 are C, substituted with R1, and A2 is N;
 R2 is H, (1-4C)alkyl or (1-4C)alkenyl; and
 R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and
 R4 is cyclopropyl; or
 R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and
- 19. A compound according to claim 13, characterised in that
 A1, A3, A4 and A5 are C;
 A2 is N;
 R1 is H

R4 is cyclopropyl.

41

R2 is methyl;

R3 is H;

R4 is cyclopropyl;

R5 is H.

5

30

20. A compound according to claim 13, characterised in that

A1, A3, A4 and A5 are C;

A2 is N;

R1 is H

10 R2 is ethenyl;

R3 is H;

R4 is cyclopropyl;

R5 is H.

- 15 21. The compound of any one of claims 1-20 for use in therapy.
 - 22. A pharmaceutical composition comprising a compound according to any one of claims 1-20 and a pharmaceutically acceptable carrier.
- 20 23. A pharmaceutical composition according to claim 22 for contraception.
 - 24. A pharmaceutical composition according to claim 22 for hormone replacement therapy.
- 25 25. A pharmaceutical composition according to claim 22 for the treatment of a gynaecological disorder.
 - 26. A use of a compound according to any one of claims 1-20 for the manufacture of a medicament.
 - 27. A use of a compound according to any one of claims 1-20 for the manufacture of a contraceptive.

42

5

28. A use according to claim 26 wherein the medicament is for hormone replacement therapy or for the treatment of a gynaecological disorder.

- 29. A method of contraception comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1-20 to a subject in need thereof.
- 30. A method of treating a gynaecological disorder comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1-20 to a subject in need thereof.